TriangleNCT03333746 · OUTCOME
Immunomonitoring of Lymphocytes Subsets Including Natural Killer (NK) Cell
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- Not reported
- Unit
- Not reported
- Interval / dispersion
- Not reported
- Time frame
- Up to 3 years
What was measured
Will be explored using graphical analyses as well as summarized quantitatively.
Analysis population: data not collected and analyzed
Groups in this outcome
Treatment (Lenalidomide, Nivolumab)
Patients receive lenalidomide PO on days 1-21 and nivolumab IV over 1 hour on days 1 and 14. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Laboratory Biomarker Analysis: Correlative studies Lenalidomide: Given PO Nivolumab: Given IV Pharmacological Study: Correlative studies
| Group | Source count |
|---|---|
| Treatment (Lenalidomide, Nivolumab) | 0 |
Reported measurements
No numerical measurement classes were posted for this outcome. Missing is not zero.
Complete source fields
- denoms
- counts
- group Id
- OG000
- value
- 0
- units
- Participants
- description
- Will be explored using graphical analyses as well as summarized quantitatively.
- groups
- description
- Patients receive lenalidomide PO on days 1-21 and nivolumab IV over 1 hour on days 1 and 14. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Laboratory Biomarker Analysis: Correlative studies Lenalidomide: Given PO Nivolumab: Given IV Pharmacological Study: Correlative studies
- id
- OG000
- title
- Treatment (Lenalidomide, Nivolumab)
- population Description
- data not collected and analyzed
- reporting Status
- POSTED
- time Frame
- Up to 3 years
- title
- Immunomonitoring of Lymphocytes Subsets Including Natural Killer (NK) Cell
- type
- OTHER_PRE_SPECIFIED
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice